NovaBridge Biosciences (NBP) Research & Development (2019 - 2025)
NovaBridge Biosciences (NBP) posted quarterly Research & Development of $55.7 million for Q4 2025, up 823.02% year-over-year from $6.0 million in Q4 2024, and up 391.77% quarter-over-quarter from $11.3 million in Q3 2025.
NovaBridge Biosciences (NBP) Research & Development (2019 - 2025) Analysis & Trends
NovaBridge Biosciences (NBP) has reported Research & Development for 6 consecutive years, with $55.7 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Research & Development rose 823.02% year-over-year to $55.7 million; the TTM figure through Dec 2025 stood at $62.9 million (up 747.84% YoY), while the FY2025 annual figure was $62.9 million, up 188.95% from the prior year.
- Research & Development advanced to $55.7 million in Q4 2025 per NBP's latest filing, from $11.3 million in the prior quarter.
- Across five years, Research & Development topped out at $55.7 million in Q4 2025 and bottomed at -$143.1 million in Q4 2022.
- Historically, Research & Development has averaged -$5.4 million across 4 years, with a median of -$3.8 million in 2023.
- Annual changes were most pronounced in 2024 — Research & Development tumbled 82.64% — and 2025, when it soared 823.02%.
- NovaBridge Biosciences' Research & Development stood at -$143.1 million in 2022, then soared by 124.27% to $34.7 million in 2023, then sank by 82.64% to $6.0 million in 2024, then jumped by 823.02% to $55.7 million in 2025.
- Business Quant data shows NBP's Research & Development at $55.7 million in Q4 2025, $11.3 million in Q3 2025, and -$3.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | NovaBridge Biosciences | 215.85 Mn | 215.85 Mn | - | 55.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 55.66 Mn |
| Sep 30, 2025 | 11.32 Mn |
| Jun 30, 2025 | -3.29 Mn |
| Mar 31, 2025 | -777,000.00 |
| Dec 31, 2024 | 6.03 Mn |
| Sep 30, 2024 | -4.48 Mn |
| Jun 30, 2024 | -5.20 Mn |
| Mar 31, 2024 | -6.06 Mn |
| Dec 31, 2023 | 34.73 Mn |
| Sep 30, 2023 | -5.09 Mn |
| Jun 30, 2023 | -4.29 Mn |
| Dec 31, 2022 | -143.13 Mn |
| Dec 31, 2020 | 332.17 Mn |
| Sep 30, 2020 | -100.85 Mn |
| Dec 31, 2019 | 86.00 Mn |
| Sep 30, 2019 | -44.70 Mn |